Navigation Links
Arpida Annual General Meeting of Shareholders Approves All Board Proposals
Date:5/7/2008

REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- The Annual General Meeting of Arpida Ltd (SWX: ARPN) has approved the proposals that were put forward by the Board of Directors.

A total of 73 shareholders were present at the meeting that took place in Basel today. 6,186,266 shares were represented, or 29.3% of the total number of shares issued (21,094,104).

The following items were on the agenda.

1. Approval of the 2007 Business Report, Company Accounts and Group Accounts

The shareholders approved the 2007 Business Report, comprising the annual financial statements, the consolidated accounts and the 2007 Annual Report.

2. Discharge of the Board of Directors and of the Senior Executive Officers

The shareholders granted discharge to the Board of Directors and to the Senior Executive Officers for their actions.

3. Compensation of Losses with General Reserves

The shareholders approved the Board proposal to compensate the accumulated loss of CHF 27,079,529 with an equal amount of share premium in the general reserves.

4. Elections to the Board of Directors

Elmar Schnee and Dr Khalid Islam were elected for a three year term of office.

Dr Andre Lamotte, Dr Hans Funfschilling and Dr Matthias Staehelin were re-elected for a three-year term of office.

5. Re-election of the Auditors

The shareholders re-elected PricewaterhouseCoopers Ltd as Auditors for 2008.

6. Creation of new Capital which can be used either as Authorised Capital or Conditional Capital (replacement of Article 3ter of the Articles of Association)

The shareholders granted the Board of Directors the authorisation to create total new capital of a maximum of up to CHF 640,000 or 3.2 million Shares, either in the form of authorised or conditional capital.

7. Revision of the Articles of Association concerning Auditors

The shareholders approved the changes to the Articles of Association, caused by the change in the Swiss Code of Obligations regarding auditors.

Dr Andre Lamotte, Chairman of the Board of Directors of Arpida Ltd, commented: "We had a very constructive and stimulating discussion with our shareholders. We're delighted that each of the Board's proposals was approved. Our shareholders' support remains an important pillar for our continuing progress."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Contact:

Arpida

Dr Jurgen Raths, CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
2. Arpida Announces Conference Call on 17 April
3. Arpida Announces Agenda Items for Shareholders Meeting
4. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
5. Arpida Announces Full Year 2007 Financial Results
6. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
7. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
8. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
9. Arpida-Supported CME Symposium Available Online
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... ... long-standing innovation strategy. A website (openinnovation.pioneer.com) dedicated to connecting third-party innovators ... – trait discovery, plant breeding, enabling technologies, biologicals and digital solutions. , “DuPont ...
(Date:7/15/2017)... ... 2017 , ... Cuvette manufacturer FireflySci has been making many products ... at FFS have learned that their biggest asset was their amazing customer base. ... new products to meet the changing needs of scientists at a rapid pace. , ...
(Date:7/14/2017)... ... July 13, 2017 , ... LGC Maine Standards ... received US FDA 510 (k) clearance for use on Siemens Sysmex® CS-2500 System ... VALIDATE® D-Dimer kit, prepared using the CLSI EP06-A “equal delta” sample preparation, offers ...
(Date:7/13/2017)... , ... July 13, 2017 , ... ... accreditation in Specialty Pharmacy. URAC is the independent leader in promoting healthcare quality ... a comprehensive commitment to quality care, improved processes and better patient outcomes. ...
Breaking Biology Technology:
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
Breaking Biology News(10 mins):